赛马鲁肽
恩帕吉菲
医学
2型糖尿病
二甲双胍
中止
随机对照试验
糖尿病
内科学
胃肠病学
泌尿科
利拉鲁肽
内分泌学
作者
Helena W. Rodbard,Julio Rosenstock,Luís Henrique Santos Canani,Chaicharn Deerochanawong,Janusz Gumprecht,Søren Lindberg,Ildiko Lingvay,ANETTE L. SØNDERGAARD,Marianne Bach Treppendahl,Eduard Montanya,PIONEER 2 Investigators,Pablo Jordão Alcântara Cruz,Luis De Loredo,Cecilia Luquez,Maria Alejandra Moisello,Gustavo Akerman Augusto,Marise Lazaretti Castro,Luís Henrique Santos Canani,Branko Akrap,Tomislav Bulum
出处
期刊：Diabetes Care
[American Diabetes Association]
日期：2019-09-17
卷期号：42 (12): 2272-2281
被引量：430
摘要
Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
坚强冰枫
aaaa
滴滴答答
null
极限001
乐空思
秋风
我看看怎么个事
Nole
prigogin
v0id
Elsevier大王
h不爱科研
OK
吃葡萄不吐葡萄皮
xuan
Youdge
xing_xing
七听
皖公网安备34019202002308
